Literature DB >> 19359144

Chronic psychotropic drug treatment causes differential expression of Reelin signaling system in frontal cortex of rats.

S Hossein Fatemi1, Teri J Reutiman, Timothy D Folsom.   

Abstract

Disruption of the Reelin and GABAergic signaling systems have been observed in psychiatric disorders including autism, schizophrenia, bipolar disorder, and major depression. Less is known of therapeutic interventions that may help ameliorate the effects of these disruptions. The current study investigated whether chronic administration of psychotropic medications (clozapine, fluoxetine, haloperidol, lithium, olanzapine, and valproic acid) used in the treatment of psychiatric disorders alters levels of Reelin, its receptor Vldlr, downstream molecules Gsk3 beta, Dab-1, and Gad65/67 in rat prefrontal cortex as measured by qRT-PCR and SDS-PAGE and western blotting. qRT-PCR revealed that mRNAs for Reelin, Vldlr, Dab-1, Gsk3 beta, and Gad65 were each significantly altered by at least one of the drugs tested, and in the case of Reelin, Dab-1, and Gsk3 beta, by multiple drugs. To verify our results, we also performed SDS-PAGE and western blotting experiments. Again, several of the protein products for Reelin, Vldlr, Dab-1, Gsk3 beta, Gad65, and Gad67 were also significantly altered by multiple drugs. The present results suggest that the Reelin signaling and GABAergic systems are affected by commonly used psychotropic medications. These changes may help explain the efficacy of these drugs and provide further support for the investigation of the Reelin and GABAergic signaling systems as therapeutic targets for the treatment of neuropsychiatric diseases.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19359144     DOI: 10.1016/j.schres.2009.03.002

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  18 in total

Review 1.  Neuroglialpharmacology: myelination as a shared mechanism of action of psychotropic treatments.

Authors:  George Bartzokis
Journal:  Neuropharmacology       Date:  2012-01-28       Impact factor: 5.250

2.  L-methionine decreases dendritic spine density in mouse frontal cortex.

Authors:  Patricia Tueting; John M Davis; Marin Veldic; Fabio Pibiri; Bashkim Kadriu; Alessandro Guidotti; Erminio Costa
Journal:  Neuroreport       Date:  2010-06-02       Impact factor: 1.837

Review 3.  Deciphering the roles of glycogen synthase kinase 3 (GSK3) in the treatment of autism spectrum disorder and related syndromes.

Authors:  Mahdi Rizk; Zahraa Saker; Hisham F Bahmad; Sanaa Nabha; Hayat Harati; Youssef Fares
Journal:  Mol Biol Rep       Date:  2021-03-01       Impact factor: 2.316

Review 4.  Genomics and pharmacogenomics of schizophrenia.

Authors:  Ramón Cacabelos; Rocío Martínez-Bouza
Journal:  CNS Neurosci Ther       Date:  2010-08-16       Impact factor: 5.243

5.  Down-regulated GABAergic expression in the olfactory bulb layers of the mouse deficient in monoamine oxidase B and administered with amphetamine.

Authors:  Hsiang-Shu Yin; Kevin Chen; Jean C Shih; Tai-Wei Tien
Journal:  Cell Mol Neurobiol       Date:  2009-11-10       Impact factor: 5.046

Review 6.  The involvement of Reelin in neurodevelopmental disorders.

Authors:  Timothy D Folsom; S Hossein Fatemi
Journal:  Neuropharmacology       Date:  2012-09-07       Impact factor: 5.250

7.  Ataxia telangiectasia alters the ApoB and reelin pathway.

Authors:  Júlia Canet-Pons; Ralf Schubert; Ruth Pia Duecker; Roland Schrewe; Sandra Wölke; Matthias Kieslich; Martina Schnölzer; Andreas Chiocchetti; Georg Auburger; Stefan Zielen; Uwe Warnken
Journal:  Neurogenetics       Date:  2018-10-21       Impact factor: 2.660

8.  Convergent functional genomics of schizophrenia: from comprehensive understanding to genetic risk prediction.

Authors:  M Ayalew; H Le-Niculescu; D F Levey; N Jain; B Changala; S D Patel; E Winiger; A Breier; A Shekhar; R Amdur; D Koller; J I Nurnberger; A Corvin; M Geyer; M T Tsuang; D Salomon; N J Schork; A H Fanous; M C O'Donovan; A B Niculescu
Journal:  Mol Psychiatry       Date:  2012-05-15       Impact factor: 15.992

9.  Overexpression of Reelin prevents the manifestation of behavioral phenotypes related to schizophrenia and bipolar disorder.

Authors:  Cátia M Teixeira; Eduardo D Martín; Ignasi Sahún; Nuria Masachs; Lluís Pujadas; André Corvelo; Carles Bosch; Daniela Rossi; Albert Martinez; Rafael Maldonado; Mara Dierssen; Eduardo Soriano
Journal:  Neuropsychopharmacology       Date:  2011-08-03       Impact factor: 7.853

10.  Vldlr overexpression causes hyperactivity in rats.

Authors:  Keiko Iwata; Nobuo Izumo; Hideo Matsuzaki; Takayuki Manabe; Yukiko Ishibashi; Yukio Ichitani; Kazuo Yamada; Ismail Thanseem; Ayyappan Anitha; Mahesh Mundalil Vasu; Chie Shimmura; Tomoyasu Wakuda; Yosuke Kameno; Taro Takahashi; Yasuhide Iwata; Katsuaki Suzuki; Kazuhiko Nakamura; Norio Mori
Journal:  Mol Autism       Date:  2012-10-30       Impact factor: 7.509

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.